CervoMed Inc. Deferred Offering Costs
CervoMed Inc. (CRVO) had Deferred Offering Costs of $320.58 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2026-08-07
- 2026-06-30: Deferred Offering Costs $320.58K.
- 2026-03-31: Deferred Offering Costs $493.60K.
- 2025-12-31: Deferred Offering Costs $320.58K.
- 2025-09-30: Deferred Offering Costs $269.33K.
| Period end | Deferred Offering Costs |
|---|---|
| 2026-06-30 | $320.58K 10-Q · filed 2026-08-07 |
| 2026-03-31 | $493.60K 10-Q · filed 2026-05-15 |
| 2025-12-31 | $320.58K 10-Q · filed 2026-08-07 |
| 2025-09-30 | $269.33K 10-Q · filed 2025-11-07 |
| 2025-06-30 | $224.93K 10-Q · filed 2025-08-08 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-13 |
| 2024-03-31 | $247.67K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $0.00 10-Q · filed 2024-05-14 |
| 2023-06-30 | $1.06M 10-Q · filed 2024-08-09 |
| 2023-03-31 | $638.02K 10-Q · filed 2024-05-14 |
| 2017-06-30 | $93.00K 10-Q · filed 2017-08-14 |
| 2016-12-31 | $200.00K 10-Q · filed 2017-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |